The effect of continuous veno-venous hemofiltration or direct hemoperfusion with polymyxin B-immobilized fiber on neutrophil respiratory oxidative burst in patients with sepsis and septic shock.
Neutrophil activates and injures tissues and organs during sepsis or septic shock. Blood purification therapies such as continuous veno-venous hemofiltration (CVVH) and direct hemoperfusion with polymyxin-immobilized fiber (PMX-DHP) have been used for the treatment of sepsis and septic shock, however, the effects of such therapies on neutrophil activation have previously been poorly understood. We sought to evaluate neutrophil reactive oxygen species (ROS), especially H2O2 production, in the pathophysiology of sepsis or septic shock and the effect of CVVH or PMX-DHP on neutrophil ROS. Seven critically ill septic patients requiring CVVH (and 12 matched septic patients who did not require CVVH as control) and seven septic shock patients treated with PMX-DHP were studied. We found that patients with sepsis or septic shock had significantly higher levels of neutrophil ROS compared with normal volunteers (183 +/- 42, 292 +/- 90, and 103 +/- 30) (P < 0.05, and < 0.005). Neutrophil ROS did not change over time in patients treated either with CVVH or without CVVH. In contrast, neutrophil ROS significantly inhibited PMX-DHP treatment in patients with septic shock (pretreatment; 292 +/- 88 vs. post-treatment; 205 +/- 93, P < 0.05). In conclusion, neutrophil ROS was significantly enhanced in the sepsis or septic shock affected patients. CVVH did not affect neutrophil ROS while PMX-DHP significant inhibited neutrophil ROS.
Naka
Toshio
T
Department of Critical Care Medicine, Wakayama Medical University, Wakayama, Japan. tnaka@wakayama-med.ac.jp
Shinozaki
Masahiro
M
Akizawa
Tadao
T
Shima
Yukihiro
Y
Takaesu
Hideki
H
Nasu
Hideki
H
D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D005260:Female; D006440:Hemofiltration; D006464:Hemoperfusion; D006801:Humans; D008297:Male; D018375:Neutrophil Activation / Q000502:physiology*; D011112:Polymyxin B / Q000008:administration & dosage*; D016897:Respiratory Burst / Q000502:physiology*; D018805:Sepsis / Q000503:physiopathology / Q000628:therapy*; D012772:Shock, Septic / Q000503:physiopathology / Q000628:therapy*
D000900:Anti-Bacterial Agents; D011112:Polymyxin B